NIH-funded research R01 grant

Investigating a receptor linked to borderline personality disorder and suicide risk

Official title: in vivo investigation of KOR as a marker of BPD and suicide related endophenotypes

Funded at Yale University · NIH-11080285 · Data updated 2026-11-12

This study is looking at how a specific brain receptor might affect emotions and behaviors in people with borderline personality disorder, which can increase the risk of suicide, to help find better treatments and prevention methods.

More Suicide research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionYale University
NIH-funded
Lab location1 site (New Haven, United States)
Project startJune 20, 2023
Project endApril 30, 2028
Funding year2025
Award (this year)$688,228
NIH project number5R01MH131720-03
Project IDNIH-11080285 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with borderline personality disorder, particularly those under 21 years old.

Less likely to help

Patients without a diagnosis of borderline personality disorder or those over 21 years old may not benefit from this research.

What this research studies

This research explores the role of the kappa opioid receptor (KOR) in borderline personality disorder (BPD), a condition that significantly increases the risk of suicide. By utilizing advanced imaging techniques like MRI, the study aims to identify how KOR affects emotional regulation, social behavior, and impulsivity in individuals with BPD. The goal is to uncover molecular mechanisms that contribute to BPD symptoms and suicide risk, which could lead to the development of new treatments and prevention strategies. The research also considers sex differences in BPD, particularly how they influence treatment access and outcomes.

Why it matters

Potential benefit: If successful, this research could lead to new treatment options that more effectively address the symptoms of BPD and reduce suicide risk.

How similar studies have gone: Other research has shown promising results in understanding the role of neurobiological factors in BPD, making this approach both relevant and potentially impactful.

Where this research is happening

  • Yale University
    New Haven, United States
    Active

Researchers

  • Principal investigator: Davis, Margaret Taylor — Yale University
  • Study coordinator: Davis, Margaret Taylor

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.